Costamare Inc. (CMRE) Financials Nov 18, 2014, 1:36
Costamare Inc. (CMRE) Financials Nov 18, 2014, 1:36 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Costamare Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 399.94M 353.15M 382.16M 386.16M 414.25M
Cost of Goods Sold (COGS) incl. D&A 196.72M 194.11M 204.4M 209.38M 220.66M
COGS excluding D&A 117.59M 112.93M 117.45M 120.87M 122.62M
Depreciation & Amortization Expense 79.13M 81.18M 86.94M 88.51M 98.04M
Depreciation 71.15M 70.89M 78.8M 80.33M 89.96M
Amortization of Intangibles 0 0 - - -
Gross Income 203.22M 159.04M 177.76M 176.78M 193.59M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 13.95M 12.48M 20.31M 19.22M 25.1M
Research & Development 0 0 0 0 -
Other SG&A 13.95M 12.48M 20.31M 19.22M 25.1M
Other Operating Expense 0 0 0 0 0
Unusual Expense (5.6M) 56.3M 61.09M 48.82M (6.55M)
EBIT after Unusual Expense 5.6M (56.3M) (61.09M) (48.82M) 6.55M
Non Operating Income/Expense (33.55M) 7.38M 6.44M (7.65M) (1.24M)
Non-Operating Interest Income 2.67M 1.45M 477,000 1.5M 543,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 47.05M 17.87M 15.69M 21.45M 71.94M
Gross Interest Expense 47.52M 19.48M 21.22M 29.93M 83.04M
Interest Capitalized 466,000 1.62M 5.53M 8.48M 11.1M
Pretax Income 116.93M 81.22M 87.59M 81.13M 102.4M
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 692,000
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 116.93M 81.22M 87.59M 81.13M 103.09M
Minority Interest Expense 0 0 0 0 0
Net Income 116.93M 81.22M 87.59M 81.13M 103.09M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 116.93M 81.22M 87.59M 81.13M 103.09M
Preferred Dividends 0 0 0 0 1.54M
Net Income Available to Common 116.93M 81.22M 87.59M 81.13M 101.55M
EPS (Basic) 1.94 1.65 1.45 1.20 1.36
Basic Shares Outstanding 60.3M 49.11M 60.3M 67.61M 74.8M
EPS (Diluted) 1.94 1.65 1.45 1.20 1.36
Diluted Shares Outstanding 60.3M 49.11M 60.3M 67.61M 74.8M
EBITDA 268.4M 227.74M 244.39M 246.07M 266.53M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...
Continue Reading
Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...
Continue Reading
The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...
Continue Reading
Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...
Continue Reading
Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...
Continue Reading
Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...
Continue Reading
Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...
Continue Reading
Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...
Continue Reading
Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Doximity's Market Standing Doximity's short percent of float has recently seen a notable reduction of 13.66%, indicating a shift in investor sentiment. With a current report showing 4.97 million shares sold short, which constitutes 3.73% of all regular shares available, traders are now called to pay attention to the stock dynamics at play. The average...
Continue Reading
HS Veitur hf. Unveils Annual Financial Report In a recent meeting, the board of HS Veitur hf. announced the approval of the annual financial report for the year 2024. This year-end report showcases the company’s achievements and financial health. Review of 2024's Financial Performance The annual report indicates a promising financial year for HS Veitur hf., reflecting...
Continue Reading
Elis SA's Recent Share Buyback Activities Elis SA has made a mark with its recent trading activities associated with its own shares, particularly highlighting a series of transactions carried out during a specified period. Overview of the Buyback Program As part of its strategic financial planning, Elis has engaged in a buyback program that has garnered attention. The...
Continue Reading
From the U.K. to the U.S.: SURI's Bold Move There's nothing quite like making a splash stateside when you're a brand outta the U.K. And that's exactly what SURI, an oral care company, aimed to do in 2026. Typically, breaking into a new market is like wrestling a bear—one wrong move and you're toast. But SURI managed to pull it off without beefing up their headcount,...
Continue Reading
Stellantis Annual General Meeting Outcomes Stellantis N.V. recently held a significant Annual General Meeting where notable resolutions received the green light from shareholders. The meeting, attended in person and streamed online, showcased Stellantis' commitment to engaging with its stakeholders. Dividend Distribution Approved One of the key highlights was the approval...
Continue Reading